Predictive factors for prolonged remission after autologous hematopoietic stem cell transplantation in young patients with type 1 diabetes mellitus

Cytotherapy
Hang XiangQiang Zeng

Abstract

Autologous hematopoietic stem cell transplantation (auto-HSCT) followed by immunoablation is a promising therapy for type 1 diabetes mellitus (T1DM) treatment due to the immunosuppression and immunomodulation mechanisms. Indeed, a considerable number of patients have been able to discontinue insulin use with this treatment. However, nonresponse and relapse occur after auto-HSCT. It is important to select the patients who can potentially benefit from this treatment, but the factors that might influence the therapeutic outcome are unclear. The objective of this study was to explore the predictors for prolonged remission after auto-HSCT therapy. The data for this study were extracted from an open-label prospective study, which was performed to treat new-onset T1DM patients with auto-HSCT. The 128 patients were categorized into insulin-free (IF) or insulin-dependent (ID) groups according to their response to treatment during the follow-up. We compared the baseline data of the two groups and explored possible prognostic factors and their odd ratios (ORs) with univariate analysis and multivariate logistic regression. Receiver operating characteristic curves (ROC) were performed to test the model discrimination function. During a foll...Continue Reading

References

Apr 12, 2007·JAMA : the Journal of the American Medical Association·Júlio C VoltarelliRichard K Burt
Jan 1, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Göran DahllöfJean E Sanders
Jul 16, 2008·Autoimmunity Reviews·Mikael Knip, Heli Siljander
Oct 30, 2008·Autoimmunity·Carlos Eduardo Barra Couri, Júlio César Voltarelli
Apr 2, 2009·American Journal of Hematology·Yuho NajimaHisashi Sakamaki
Oct 15, 2009·Diabetology & Metabolic Syndrome·Júlio C Voltarelli, Carlos Eduardo Barra Couri
Dec 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul A HoffmeisterJean E Sanders
Mar 24, 2010·Pediatric Clinics of North America·Francesca MilanettiRichard K Burt
Aug 25, 2011·Endocrine Reviews·Paolo FiorinaNicholas Zavazava
Sep 24, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Rene Joukhadar, Ken Chiu
Jan 10, 2012·Seminars in Hematology·Uma GunasekaranShubhada M Jagasia
Nov 28, 2012·La Presse médicale·Christian Boitard
Jul 13, 2013·Investigative Ophthalmology & Visual Science·Monique S RoyRobert Donnelly

❮ Previous
Next ❯

Citations

Apr 27, 2018·Frontiers in Immunology·Kayleigh M van MegenBart O Roep

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.